Literature DB >> 23076533

Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.

Nur Selvi1, Burçin Tezcanlı Kaymaz, Handan Haydaroğlu Sahin, Mustafa Pehlivan, Cağdaş Aktan, Ayşegül Dalmızrak, Ezgi Inalpolat, Buket Kosova, Mehmet Yılmaz, Vahap Okan, Güray Saydam.   

Abstract

The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23076533     DOI： 10.1007/s11033-012-2207-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  25 in total

1.  Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

Authors:  Giovanni Martinelli; Michele Malagola; Emanuela Ottaviani; Gianantonio Rosti; Elena Trabacchi; Michele Baccarani
Journal:  Haematologica       Date:  2004-02       Impact factor: 9.941

2.  MDCT evaluation of cardiac involvement in hypereosinophilic syndrome: differentiating mural thrombus, infarcted, and noninfarcted myocardium by delayed-phase scanning.

Authors:  Chuan-Han Chen; I-Chen Tsai; Sheng-Ling Jan; Wei-Lin Tsai; Clayton Chi-Chang Chen
Journal:  Tex Heart Inst J       Date:  2011

3.  [Hypereosinophilic syndrome and renal insufficiency].

Authors:  G Garella; L Marra
Journal:  Minerva Urol Nefrol       Date:  1990 Apr-Jun       Impact factor: 3.720

4.  Heart failure mimicking prior myocardial infarction in a patient with idiopathic hypereosinophilic syndrome.

Authors:  Celina Wojciechowska; Anna Gala; Agnieszka Kuczaj; Wojciech Jachec; Ala Foremny; Grzegorz Helbig; Romuald Wojnicz; Ewa Nowalany-Kozielska
Journal:  Int Heart J       Date:  2011       Impact factor: 1.862

Review 5.  World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.

Authors:  Jason Gotlib
Journal:  Am J Hematol       Date:  2011-08       Impact factor: 10.047

6.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

Review 7.  [Eosinophilia and renal pathology].

Authors:  C P Giudicelli; F Didelot; C Duvic; J Desrame; M Herody; G Nedelec
Journal:  Med Trop (Mars)       Date:  1998

8.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

9.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

Authors:  Jorge Cortes; Patricia Ault; Charles Koller; Deborah Thomas; Alessandra Ferrajoli; William Wierda; Mary B Rios; Laurie Letvak; Elizabeth S Kaled; Hagop Kantarjian
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

10.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors:  Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.